Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Ipamorelin vs Sermorelin 2026 analysis compares growth hormone peptide mechanisms, regulatory status, and prescription telehealth access pathways.
-
MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs
Analysis examines MEDVi's compounded GLP-1 semaglutide telehealth model, FDA compounding framework, and prescription weight loss trends for 2026.
-
NAD+ research examines cellular aging as telehealth expands peptide therapy access — RenuviaRX platform model, pricing, and oversight revealed.
-
Best peptides for skin care: Consumer analysis examines injectable Glutathione tripeptide vs topical delivery for January 2026 wellness planning.
-
January 2026 consumer analysis compares oral Wegovy, compounded sublingual semaglutide, and tirzepatide drops across pricing and access formats.
-
Industry analysis compares FDA-approved Wegovy pricing from $149 oral to Ro's $199 injectable as telehealth access expands for 2026.
-
Analysis examines best tirzepatide access pathways for 2026 including FDA regulatory changes, insurance coverage shifts, and cash-pay options.
-
FDA approves first oral GLP-1 for weight loss as patients evaluate Wegovy, Zepbound, and compounded options. MEDVi lists programs from $179.
-
Independent analysis reviews best TRT injection for 2026 as Fridays lists prescription testosterone in injectable and oral telehealth formats.
-
Sprout Health lists prescription NAD+ injections at $149 first month through telehealth platform as consumer interest in compounded NAD+ grows.